Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D3TQ
|
|||
| Drug Name |
GSK2330811
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Systemic sclerosis [ICD-11: 4A42; ICD-9: 710.1] | Phase 2 | [2], [3] | ||
| Company |
GlaxoSmithKline Research Triangle Park, NC
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oncostatin-M (OSM) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | GMCSF-mediated signaling events | |||
| IL3-mediated signaling events | ||||
| WikiPathways | Oncostatin M Signaling Pathway | |||
| Adipogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04151225) Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease (COSMIS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.